Events Manager

Deadline alert: Doximity, Inc. investors have until November 16, 2026 to seek lead plaintiff role in securities fraud Class Action, Glancy Prongay Wolke & Rotter LLP reminds. Class action covers investors who bought Doximity, Inc. securities between August 8, 2024 and May 13, 2026; complaint alleges the company failed to disclose material adverse facts. LOS ANGELES, Oct. 19, 2026 (GLOBE NEWSWIRE) - Investors in Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) have until November 16, 2026 to ask the Court to appoint them lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Doximity, Inc. securities between August 8, 2024 and May 13, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today reminded investors of the upcoming deadline. The Doximity, Inc. case, Michigan Laborers' Pension Fund v. Doximity Inc., et al., was filed on September 16, 2026 and is pending in the U.S. District Court for the Northern District of California (Case No. 3:26-cv-10529). Investors who suffered losses on Doximity, Inc. investments can contact Glancy about the Doximity, Inc. class action to learn about potentially pursuing claims under the federal securities laws before the November 16, 2026 deadline. Deadline and key dates for Doximity, Inc. investors * Lead plaintiff deadline: November 16, 2026 * Class period: August 8, 2024 to May 13, 2026, inclusive * Complaint filed: September 16, 2026 * Court: U.S. District Court for the Northern District of California What happened? On November 6, 2025, Doximity announced financial results for the second quarter of 2026, in which the Company expressed a degree of caution regarding the outlook for ad spending and implied a slowdown in sales growth in the second half of the 2026 fiscal year, which ended on March 31, 2026. On this news, Doximity stock fell $8.29 or 13.25%, to close at $54.29 per share on November 7, 2025, thereby injuring investors. Then, on February 5, 2026, Doximity announced financial results for the third quarter of 2026, in which the Company lowered its revenue guidance for 2026 full fiscal year and announced that its sales growth had decelerated while its net income had contracted, which will negatively impact its 2026 fiscal fourth quarter. On this news, Doximity stock fell $5.59 or 16.78%, to close at $27.73 per share on February 6, 2026, thereby further injuring investors. Finally, on May 13, 2026, Doximity announced financial results for the fourth quarter and full year 2026, in which the Company revealed it missed its already-reduced revenue guidance, as well as projected a significantly slower pace of growth for its 2027 fiscal year, which ends on March 31, 2027. On this news, Doximity stock fell $5.38 or 23%, to close at $18.01 on May 14, 2026, thereby further injuring investors. What does the Doximity, Inc. complaint allege? The Doximity, Inc. securities lawsuit alleges that, throughout the class period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Doximity, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose to investors that: (1) Doximity overstated the impact that its Newsfeed had on its revenue growth; (2) the Company was losing market share to its competitors with more favorable pricing and engagement models; (3) the Company was using banner ads and e-newsletters instead of deep engagement tactics; and (4) as a result, defendants' positive statements about Doximity, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Investors who purchased or otherwise acquired Doximity, Inc. securities during the class period may move the Court no later than November 16, 2026 to request appointment as lead plaintiff in this putative class action lawsuit. "The complaint filed against Doximity, Inc. alleges that, among other things, the Company failed to disclose that Doximity overstated the impact that its Newsfeed had on its revenue growth. Investors who want to help lead this case must ask the Court by November 16, 2026, and that date is coming soon," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP. What's the next step? Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm that can help Doximity, Inc. investors evaluate potential claims to recover their losses. Investors who wish to serve as lead plaintiff in the Doximity, Inc. class action must move the Court by November 16, 2026. To learn more, visit the Doximity, Inc. case page, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224). If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the Doximity, Inc. class, you need not take any action at this time. You may retain counsel of your choice or take no action and remain an absent class member. No class has been certified yet in the Doximity, Inc. case. Frequently Asked Questions Who is eligible? Investors who purchased or otherwise acquired Doximity, Inc. securities between August 8, 2024 and May 13, 2026 and suffered losses may be members of the proposed class in the Doximity, Inc. shareholder lawsuit. When is the Doximity, Inc. lead plaintiff deadline? Motions to serve as lead plaintiff in the Doximity, Inc. class action must be filed with the U.S. District Court for the Northern District of California by November 16, 2026. What if I miss the Doximity, Inc. deadline? After November 16, 2026, investors generally can no longer ask to be appointed lead plaintiff, but Doximity, Inc. investors may still remain class members. Their ability to share in any future recovery does not depend on serving as lead plaintiff. What is a lead plaintiff? In the Doximity, Inc. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff. Does it cost anything to contact Glancy or participate in this action? Glancy represents Doximity, Inc. investors on a contingency fee basis, which means investors pay no attorneys' fees unless there is a recovery. Any fees are subject to court approval and are paid from the recovery. Why work with Glancy on the Doximity, Inc. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Doximity, Inc. class action. Prior results do not guarantee a similar outcome. About Glancy Prongay Wolke & Rotter LLP Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025. Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome. Glancy Prongay Wolke & Rotter LLP 1925 Century Park East, Suite 2100 Los Angeles, CA 90067 Email: [email protected] Telephone: 310-201-9150 | Toll-free: 888-773-9224

Doximity (NYSE:DOCS) stock: insider Siddharth Sitaram sells 2,613 shares. October 16, 2026 Key points. * Doximity CAO Siddharth Sitaram sold 2,613 shares at an average price of $30.68, generating $80,166.84. The Rule 10b5-1 sale was intended to cover tax withholding on vested equity awards, leaving him with 101,432 shares. * Doximity shares traded near $30.81, with a $5.49 billion market capitalization. The company recently beat quarterly EPS estimates, reporting $0.29 versus the $0.16 consensus, while revenue rose 7.3% year over year to $156.62 million. * Analyst sentiment is mixed, with the stock carrying an overall "Hold" rating and an average price target of $30.73. Doximity also faces a securities-fraud class-action overhang, alongside continued institutional ownership of 87.19%. * Five stocks we like better than Doximity. Doximity, Inc. (NYSE:DOCS - Get Free Report) CAO Siddharth Sitaram sold 2,613 shares of Doximity stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total transaction of $80,166.84. Following the completion of the sale, the chief accounting officer owned 101,432 shares in the company, valued at approximately $3,111,933.76. This trade represents a 2.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Siddharth Sitaram also recently made the following trade(s): * On Tuesday, September 15th, Siddharth Sitaram sold 2,077 shares of Doximity stock. The shares were sold at an average price of $26.02, for a total transaction of $54,043.54. * On Thursday, August 13th, Siddharth Sitaram sold 1,770 shares of Doximity stock. The shares were sold at an average price of $24.94, for a total value of $44,143.80. Doximity stock performance. Shares of NYSE DOCS traded down $0.69 during mid-day trading on Friday, hitting $30.81. 3,582,714 shares of the stock traded hands, compared to its average volume of 3,989,128. The company has a market cap of $5.49 billion, a price-to-earnings ratio of 36.25, a PEG ratio of 23.40 and a beta of 1.22. The stock has a fifty day moving average price of $26.68 and a 200-day moving average price of $23.58. Doximity, Inc. has a 52 week low of $17.15 and a 52 week high of $71.37. Discover more Doximity (NYSE:DOCS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.13. The firm had revenue of $156.62 million for the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The business's quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.36 EPS. As a group, sell-side analysts predict that Doximity, Inc. will post 0.74 EPS for the current fiscal year. Analyst ratings changes. A number of research analysts recently weighed in on the company. Freedom Capital lowered Doximity from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 8th. Bank of America reaffirmed an "underperform" rating and issued a $20.00 target price (down from $38.00) on shares of Doximity in a report on Monday, June 29th. Truist Financial upped their target price on shares of Doximity from $19.00 to $24.00 and gave the stock a "hold" rating in a research note on Thursday, August 13th. Piper Sandler reiterated an "overweight" rating and issued a $47.00 target price (up from $42.00) on shares of Doximity in a research note on Friday, August 7th. Finally, Citigroup cut shares of Doximity to an "underperform" rating in a report on Monday, June 29th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $30.73. Here are the key news stories impacting Doximity this week: * Doximity extended its 13-year alliance with U.S. News, supporting physician searches, appointment booking and hospital rankings. The partnership could reinforce user engagement and patient-access offerings. * Doximity will release fiscal 2027 second-quarter results on November 5, giving investors the next major opportunity to assess growth, advertising trends and management's outlook. * Several law firms publicized a securities-fraud class action against Doximity and certain individuals, including co-founder and former Chief Strategy Officer Nate Gross. The allegations reportedly concern statements that Doximity could gain market share while older advertising formats were losing ground to programmatic and social-media competitors; the claims have not been established in court. * Investors who purchased DOCS shares between August 8, 2024 and May 13, 2026 are being reminded that November 16, 2026 is the deadline to seek appointment as lead plaintiff. Repeated announcements from Robbins Geller, SBS Law, Kaplan Fox, Rosen, Pomerantz, Bronstein Gewirtz Grossman and other firms increase the visibility of the legal overhang and could weigh on sentiment. Institutional trading of Doximity. A number of institutional investors have recently made changes to their positions in DOCS. Versant Capital Management Inc raised its holdings in shares of Doximity by 1,176.9% during the third quarter. Versant Capital Management Inc now owns 1,826 shares of the company's stock valued at $52,000 after purchasing an additional 1,683 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Doximity by 111.0% in the first quarter. Parallel Advisors LLC now owns 2,560 shares of the company's stock worth $60,000 after purchasing an additional 1,347 shares during the last quarter. Fortitude Family Office LLC boosted its holdings in Doximity by 31,271.4% in the third quarter. Fortitude Family Office LLC now owns 2,196 shares of the company's stock worth $62,000 after purchasing an additional 2,189 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Doximity by 937.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,833 shares of the company's stock worth $66,000 after purchasing an additional 2,560 shares during the period. Finally, Continuum Advisory LLC bought a new stake in Doximity in the 2nd quarter worth approximately $67,000. Hedge funds and other institutional investors own 87.19% of the company's stock. Doximity company profile. Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources. The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals. Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Doximity, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list. While Doximity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy. Continue following MarketBeat